David VanderWeele, MD, PhD
Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine
Research Program
- Translational Research in Malignancy (TRIM)
Cancer-Focused Research
Cancer heterogeneity and evolution with a goal of identifying and targeting drivers of cancer progression and therapy resistance. His research has described intrafocal heterogeneity in prostate cancer, with implications for response to targeted therapy; interfocal heterogeneity with enrichment for alterations in targetable pathways in aggressive variants of prostate cancer; heterogeneity of loss of the PTEN tumor suppressor gene and correlation with imaging features; and methods to track molecular changes in late stage disease using liquid biopsy, with implications for therapy resistance. He continues to pursue clinical and translational research projects to precisely target aggressive prostate cancer.